Introduction
============

Ankylosing spondylitis (AS) is a type of chronic rheumatic disease with chronic inflammation of axial joint as the main type, and characterized by sacroiliitis and spondylitis, which mainly involves the sacroiliac joint, spinal apophysis, paravertebral soft tissues and peripheral joints. AS is usually accompanied with extra-articular manifestations ([@b1-etm-0-0-6220]). The prevalence rate of AS is different in different region, and prevalence rate of this disease is approximately 0.3% in China. Males were more prone to be affected with AS and male/female ratio is approximately 2--3:1, AS mainly affects people aged 13--31 years, and the highest incidence was observed in people aged 20--30 years, while occurrence of AS in people aged above 40 years and below 8 years is rare. With the progress of science and technology and deepening of research, considerable progresses have been made in the diagnosis and treatment of AS. It has been proved that the human leucocyte antigen (HLA)-B27 is closely related with the occurrence of AS ([@b2-etm-0-0-6220]), but the exact pathogenesis of AS remains unknown.

Inflammation and hyperostosis are the main pathological changes in AS. Pathological new bone formation can cause osteophyte, resulting in spinal and sacroiliac joint ankylosis. In addition to inflammation and hyperostosis, osteoporosis (OP) is also a widely-recognized complication in AS patients. In the early stages of disease, lesions in bone trabeculae may increase the risk of vertebral fractures and cause severe nerve injury ([@b3-etm-0-0-6220]). There are approximately 19--62% of AS patients who suffer from OP, and 9--42% of AS patients are complicated with vertebral fractures ([@b4-etm-0-0-6220],[@b5-etm-0-0-6220]). Hyperostosis and OP, as two opposite processes, bring great challenges to the clinical diagnosis and treatment of AS. The prevention and treatment of hyperostosis may aggravate OP, and vice versa.

In this study, BLAB/c mice were used as subjects. AS was induced using proteoglycan, and OP was induced using the tail suspension method. Moreover, the model of AS mouse complicated with OP was established to study and compare the changes in bone mineral density and bone metabolic indexes, so as to provide references for clinical diagnosis and treatment of AS.

Materials and methods
=====================

### Animals

Forty BLAB/c healthy female mice in clean grade aged 8 weeks, weighing 20.5±2 g, were provided by Laboratory Animal Center of Guangdong Medical University. Mice were randomly divided into four groups with 10 mice in each group. Mice were fed in separate cages at room temperature 22±1°C under the relative humidity of 60--70% with free access to water and food. All animal experiments were approved by the Animal Ethics Committee of Affiliated Hospital of Guangdong Medical University (Zhanjiang, China).

### Materials and reagents

Proteoglycan (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA); Freund\'s complete adjuvant (Sigma; Merck KGaA, Darmstadt, Germany); Freund\'s incomplete adjuvant (Sigma; Merck KGaA); calcium (Ca) assay kit (standard colorimetric method), phosphorus assay kit (standard colorimetric method), alkaline phosphatase (ALP) assay kit and tartrate-resistant acid phosphatase (TRACP) kit were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China); 721 spectrophotometer (Shanghai Precision and Scientific Instrument Co., Ltd, Shanghai, China); electronic analytical balance (Shanghai Precision and Scientific Instrument Co., Ltd.); small animal dual-energy X-ray bone densitometer (AA400, Kodak, Rochester, NY, USA); AG-1S universal material tester (Ag-1S, Panasonic, Tokyo, Japan).

### Establishment of AS mouse model (AS group)

AS mouse model was established according to the standard method of proteoglycan induced AS ([@b6-etm-0-0-6220]--[@b8-etm-0-0-6220]). Multiple joint synovitis including spondylitis, ankylosis and malformation proved that the model was successfully established. Ten susceptible BLAB/c mice were adaptively fed for 1 week and then AS was induced using proteoglycan. Each mouse was injected intraperitoneally with 0.15 ml proteoglycan emulsion (100 µg proteoglycan + Freund\'s complete adjuvant), followed by another intraperitoneal injection of 0.15 ml proteoglycan emulsion (100 µg proteoglycan + Freund\'s incomplete adjuvant) at the 3rd and 6th week.

### Establishment of OP mouse model (OP group)

After adaptive feeding for 5 weeks, OP mouse model was established using tail suspension method. Mice were suspended via tail-suspension rotating device to hang the posterior limbs. Posterior limbs were kept in an artificial weightless state. Mice were allowed to move freely in vertical direction without damaging the tail. Mice were observed every day and the suspension position was adjusted according to the situation. Mice were suspended for 5 weeks.

### Establishment of model of AS mice complicated with OP (AS + OP group)

Mouse model of AS complicated with OP was established using proteoglycan combined with tail suspension method. After adaptive feeding for 1 week, each mice were injected intraperitoneally with 0.15 ml proteoglycan emulsion (100 µg proteoglycan + Freund\'s complete adjuvant), followed by intraperitoneal injection of 0.15 ml proteoglycan emulsion (100 µg proteoglycan + Freund\'s incomplete adjuvant) at the 3rd and 6th week. Mice were suspended via tail using the tail-suspension rotating device 5 weeks after the beginning in the same way as described in 'Establishment of OP mouse model (OP group)'. Modeling was sustained for 10 weeks.

### Determination of bone mineral density of mice

Mice were sacrificed by via cervical dislocation. One femur, tibia and lumbar vertebrae bone were collected and the soft tissues attached to the bone tissues were removed. Femur and lumbar vertebrae bone were wrapped with the gauze impregnated with normal saline, and stored at −20°C. Tibia was fixed with formaldehyde solution for the detection of morphometric indexes. Bone mineral density was measured using the dual-energy X-ray bone densitometer (Kodak, Rochester, NY, USA).

### Bone biomechanical determination

The 3-point bending test was performed on tibia of mice, and the tibia was pressed using the AG-1S universal material machine (load measurement accuracy = 0.01 N, speed = 1.5 mm/min, and span = 8 mm) until tibia rupture. Then the internal and external diameters and cortical bone thickness on the fractured end were measured. The load-deformation curve was plotted according to the results, the maximum load was recorded, and the bending elastic modulus was calculated ([@b9-etm-0-0-6220]).

### Determination of bone metabolic indexes

The eyeballs were removed from mice to collect blood, and the blood was centrifuged at 2,500 × g to collect serum. Then the serum Ca, ALP and TRACP were detected according to the instructions.

### Statistical analysis

Statistical Product and Service Solutions (SPSS) 17.0 software (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis of all data. Data were presented as mean ± standard deviation. Analysis of variance followed by post hoc test (Least Significant Difference) was used for comparisons among multiple groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### General conditions of mice

Mice were observed and the situations were recorded every day. All mice were in good condition during the experiment and there was no obvious infection or accidental death. Toe swelling began to occur in limbs of AS mouse model at 3 weeks after injection of proteoglycan, and symptoms were aggravated with the prolonged treatment. Multi-joint synovitis, including spondylitis, occurred, resulting in dynamic joint ankylosis and deformity, which prove that the model was successfully established. The weight of mice in each group before the experiment was compared by using the variance analysis. Weight of mice in each group showed no significant difference to the pretreatment level (F=0.95, P=0.88). With the increase of time, the body weight of each group increased obviously compared with that before the experiment. t-test was used to compare the body weight of each group before experiment and before death. There was significant difference in body weight between each group before experiment and before sacrifice. The comparison between the control group and the OP group before the test and before the death was 7.09 (P\<0.01), 6.73 (P\<0.01), 6.85 (P\<0.01), 4.87 (P\<0.01) respectively. Compared with the control group, the weight of mice in the OP group was not changed significantly, while weight in the AS and the AS + OP groups reduced significantly, and weight loss in the AS + OP group was the most significant among three treatment groups (F=3.46, P=0.0025) ([Table I](#tI-etm-0-0-6220){ref-type="table"}).

### Comparison of bone mineral densities of mice in each group

Bone mineral densities of femur and lumbar vertebrae bone isolated from mice were measured using dual-energy X-ray bone densitometer. Comparison of bone mineral density among groups was performed via analysis of variance (F=8.23, P\<0.001), and significant differences were found. Bone density of femoral metaphysis and lumbar vertebrae in the OP group was significantly decreased compared with that in the control group (P\<0.001), suggesting that the OP model was established successfully. Bone mineral density in the AS group were lower than that in the control group (P=0.02), indicating that OP also exists in AS, but it was mild in the OP group. The bone mineral density in the AS + OP group was the lowest (P\<0.01) ([Table II](#tII-etm-0-0-6220){ref-type="table"}).

### Changes in bone biological activity of mice in each group

Biological activity of tibia in each group was detected using the 3-point bending method, and the maximum load and bending elastic modulus were calculated and compared. Significant differences in maximum load and bending elastic modulus were found among groups (F=4.90, P=0.006; F=5.31, P=0.002). The maximum load and bending elastic modulus in the AS, the OP and the AS + OP groups were lower than those in the control group (P\<0.05), and the lowest values were observed in the AS + OP group (P\<0.01) ([Table III](#tIII-etm-0-0-6220){ref-type="table"}).

### Comparison of bone metabolic indexes of mice in each group

Metabolic indexes in serum of mice in each group were detected. No significant differences in serum Pi were found among groups (F=2.15, P=0.12), but significant differences in contents of serum Ca (F=8.86, P\<0.001), TRACP (F=10.53, P\<0.001) and ALP (F=9.21, P\<0.001) were observed among groups. Content of serum Ca in each experimental group was significantly increased compared with that in the control group, and the highest level was observed in the AS + OP group (P\<0.01). Content of TRACP in each experimental group was also obviously increased compared with that in the control group, and the highest level was also observed in the AS + OP group (P\<0.01). Contents of ALP in the AS, the OP and the AS + OP groups were significantly decreased compared with that in the control group, and the decrease was most significant in the AS + OP groups (P\<0.01) ([Table IV](#tIV-etm-0-0-6220){ref-type="table"}).

Discussion
==========

AS is a chronic autoimmune inflammation characterized by familial aggregation. Axial skeletal lesion is common in AS patients and incidence is higher in males than in females; It has been proved that occurrence of AS is closely correlated with HLA-B27, but the pathogenesis of this disease still has not been fully elucidated. Animal model is an important tool to the study human autoimmune diseases, but HLA-B27 transgenic animal model has the shortcomings of long manufacturing cycle, mild symptoms, difficult operation, high cost and different clinical manifestations to AS ([@b10-etm-0-0-6220]). Proteoglycans can induce the progressive polyarthritis, and its progression is very similar to the clinical manifestations of AS ([@b11-etm-0-0-6220]). BALB/c mice are proteoglycan-susceptible mice. In the proteoglycan-induced BALB/c mouse model, inflammation starts in sacroiliac joint and tendon inflammation, and then gradually affects multiple intervertebral discs, which is similar to the progression of AS. Besides, incidence rate of arthritis in F2-generation mice is 43.5%, and that of spondylitis is 60%. With the advantages of simple operation, short cycle and obvious symptoms, proteoglycan-induced AS mouse model has become an important tool to study AS ([@b6-etm-0-0-6220]).

OP refers to a systemic bone metabolic disease in which low bone mass (namely the decreased bone mineral density) and abnormality in qualitative structure of bone tissues lead to increased bone fragility and decreased bone strength, easily causing fractures ([@b12-etm-0-0-6220]). OP affects approximately 9 million new cases per year worldwide, and incidence of this disease shows an increasing trend, causing serious medical and financial burden to society and family ([@b13-etm-0-0-6220]). Pain, mostly low back pain, is the most common symptom of OP. Patients with severe AS may suffer from fracture or even death ([@b14-etm-0-0-6220]). OP animal model is divided into four types ([@b15-etm-0-0-6220]): hormone intervention type ([@b16-etm-0-0-6220],[@b17-etm-0-0-6220]), disuse type ([@b18-etm-0-0-6220]), nutritional type ([@b19-etm-0-0-6220]) and other types ([@b20-etm-0-0-6220]). Tail-suspension method induces disuse type OP model. Tail-suspension-induced AS is characterized by minimal injury and simple operation.

AS patients are prone to be affected by OP. BALB/c mice were used as subjects in our study to investigate and compare the changes in bone mineral density and bone metabolism in AS mice complicated with OP. AS mouse model, OP mouse model and AS complicated with OP mouse model were established, and the changes in bone mineral density, bone biomechanics and bone metabolic indexes were compared to those of control group. It was found that the bone mineral density and bone strength in OP model were significantly decreased compared with those in the control group, indicating that the OP model was established successfully, and obvious bone destruction existed in mouse OP model. Bone mineral density and bone strength were also decreased in AS model, and the decrease in AS + OP model was most significant, indicating that bone destruction is the most serious in AS mice complicated with OP. Significant differences in serum Ca, ALP and TRACP ([@b21-etm-0-0-6220],[@b22-etm-0-0-6220]) were found in each treatment group compared with the control group. Serum Ca and TRACP were significantly increased, while ALP was decreased obviously, and the changes were most significant in AS + OP group. In this study, changes in bone mineral density and bone metabolic indexes were consistent with clinical manifestations of patients. Clinical studies showed that the incidence rates of OP and bone mass loss in AS patients were higher compared with other groups of patients, and most patients with AS combined with OP suffer from decreased bone mineral density and abnormal bone metabolism ([@b4-etm-0-0-6220],[@b23-etm-0-0-6220]).

The model of AS complicated with OP was successfully established by using BALB/c mice as the research object. The model was easy to established with short period and low cost. The changes of bone mineral density and bone metabolism were studied and compared. It is consistent with clinical manifestations, which provides a basis for further research on mechanism and drugs. There were some shortcomings in this study due to the limited resources. Only a single animal model was used in this experiment, and the results can be more reliable if the study is repeated using multiple animal models. Moreover, only the changes in bone mineral density and bone biomechanics were detected, and our future studies will try to provide more detailed information on bone changes using micro-computed tomography (CT) scanning.
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###### 

Changes in body weight of mice in each group before and after experiment.

            Weight (g)   
  --------- ------------ -------------------------------------------------------------------------------------------------------
  Control   21.55±2.08   28.87±1.98^[a](#tfn1-etm-0-0-6220){ref-type="table-fn"}^
  AS        21.71±1.99   27.23±2.08^[a](#tfn1-etm-0-0-6220){ref-type="table-fn"},[b](#tfn2-etm-0-0-6220){ref-type="table-fn"}^
  OP        21.64±2.01   28.06±1.89^[a](#tfn1-etm-0-0-6220){ref-type="table-fn"}^
  AS + OP   21.52±2.04   25.45±2.01^[b](#tfn2-etm-0-0-6220){ref-type="table-fn"}^

P\<0.05, compared with those before the experiment

P\<0.05, compared with the control group. AS, ankylosing spondylitis; OP, osteoporosis.

###### 

Comparison of bone mineral densities of mice in each group.

            Bone mineral density (g/cm^3^)                            
  --------- --------------------------------------------------------- ---------------------------------------------------------
  Control   2.15±0.27                                                 2.42±0.21
  AS        1.53±0.21^[a](#tfn3-etm-0-0-6220){ref-type="table-fn"}^   1.62±0.16^[a](#tfn3-etm-0-0-6220){ref-type="table-fn"}^
  OP        1.29±0.19^[b](#tfn4-etm-0-0-6220){ref-type="table-fn"}^   1.43±0.14^[b](#tfn4-etm-0-0-6220){ref-type="table-fn"}^
  AS + OP   1.06±0.15^[b](#tfn4-etm-0-0-6220){ref-type="table-fn"}^   1.13±0.18^[b](#tfn4-etm-0-0-6220){ref-type="table-fn"}^

P\<0.05

P\<0.01, compared with the control group. AS, ankylosing spondylitis; OP, osteoporosis.

###### 

Comparison of bone biological activity of mice in each group.

  Groups    Maximum load (N)                                           Bending elastic modulus (Gpa)
  --------- ---------------------------------------------------------- ---------------------------------------------------------
  Control   15.46±0.56                                                 1.83±0.14
  AS        13.45±0.67^[a](#tfn5-etm-0-0-6220){ref-type="table-fn"}^   1.56±0.17^[a](#tfn5-etm-0-0-6220){ref-type="table-fn"}^
  OP        11.02±0.74^[a](#tfn5-etm-0-0-6220){ref-type="table-fn"}^   1.24±0.15^[a](#tfn5-etm-0-0-6220){ref-type="table-fn"}^
  AS + OP   9.45±0.87^[b](#tfn6-etm-0-0-6220){ref-type="table-fn"}^    1.05±0.19^[b](#tfn6-etm-0-0-6220){ref-type="table-fn"}^

P\<0.05

P\<0.01, compared with the control group. AS, ankylosing spondylitis; OP, osteoporosis.

###### 

Comparison of bone metabolic indexes of mice in each group.

  Groups    Ca (mmol/l)                                               Pi (mmol/l)                                               ALP (U/l)                                                    TRACP (U/l)
  --------- --------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------
  Control   2.25±0.31                                                 2.70±0.49                                                 156.90±16.96                                                 15.23±2.40
  AS        2.48±0.25^[a](#tfn7-etm-0-0-6220){ref-type="table-fn"}^   2.71±0.38^[a](#tfn7-etm-0-0-6220){ref-type="table-fn"}^   134.34±18.73^[a](#tfn7-etm-0-0-6220){ref-type="table-fn"}^   19.34±3.02^[a](#tfn7-etm-0-0-6220){ref-type="table-fn"}^
  OP        2.69±0.28^[a](#tfn7-etm-0-0-6220){ref-type="table-fn"}^   2.65±0.46^[a](#tfn7-etm-0-0-6220){ref-type="table-fn"}^   120.38±20.76^[a](#tfn7-etm-0-0-6220){ref-type="table-fn"}^   20.34±2.99^[a](#tfn7-etm-0-0-6220){ref-type="table-fn"}^
  AS + OP   2.83±0.23^[b](#tfn8-etm-0-0-6220){ref-type="table-fn"}^   2.65±0.37^[b](#tfn8-etm-0-0-6220){ref-type="table-fn"}^   96.78±17.28^[b](#tfn8-etm-0-0-6220){ref-type="table-fn"}^    25.26±2.57^[b](#tfn8-etm-0-0-6220){ref-type="table-fn"}^

P\<0.05

P\<0.01, compared with the control group. Ca, calcium; ALP, alkaline phosphatase; TRACP, tartrate-resistant acid phosphatase; AS, ankylosing spondylitis; OP, osteoporosis.
